Announcements and news related to Biotorn being acquired at $0.33/s subject to SHs' approval are the main results. New company will deal with the CROs. MM and Biotron BOD just need to leave, creating a happy exit for the SHs, and an effective path for the Biotron tech and compounds to be under a capable company that can liase wit the CROs and progress the hitherto works to make the products available for the patients.
Biotron management should and must update the market about the financing of the project fees adn retainer fees for the C14.
MM being Tight lipped by outsourcing all works to the external parties should not be ethically entiled to the high pay. Let MM et al. take 75% of the salary after a deal. I'd be happy for the MM to receive a performance bonus after a blockbuster deal.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)